PIB TrackerIndia's bioeconomy crosses USD 195 billion mark
India's bioeconomy and the BioE3 Policy headline the India Bioeconomy Report (IBER) 2026, released at BIRAC's 14th Foundation Day.
What happened
- The Ministry of Science & Technology reported that India's bioeconomy reached USD 195.3 billion in 2025, up from roughly USD 10 billion in 2014 — a near-twentyfold rise across the decade.
- The headline numbers were carried in the India Bioeconomy Report (IBER) 2026, released alongside the BIRAC Impact Report at the 14th Foundation Day of BIRAC, the Biotechnology Industry Research Assistance Council.
- The bioeconomy now contributes about 4.8% to national GDP, has been growing at roughly 17–18% a year, and is supported by a base of over 11,800 biotech startups.
- The Government restated its target of taking the bioeconomy to USD 300 billion by 2030, anchored on the BioE3 Policy (Biotechnology for Economy, Environment & Employment) and the new Research, Development & Innovation (RDI) Fund of Rs 1 lakh crore.
- BIRAC, as a key implementer, is building bio-foundries and Bio-AI hubs to push the country up the biomanufacturing value chain.
Background & context
A "bioeconomy" is the share of economic activity that draws on biological resources, biotechnology and biological processes — turning cells, enzymes, microbes and biomass into medicines, fuels, foods, materials and industrial chemicals. It cuts across pharmaceuticals and vaccines, industrial biotech, bio-agriculture, bio-services such as clinical research, and the emerging fields of synthetic biology and bio-based manufacturing. India's measurement of this aggregate is published annually as the India Bioeconomy Report, so each year's edition is the chief reference point for the sector's size, composition and growth rate.
The institution at the centre of the announcement is BIRAC — the Biotechnology Industry Research Assistance Council, a public-sector enterprise set up under the Department of Biotechnology (DBT), which itself sits within the Ministry of Science & Technology. BIRAC is the Government's nodal agency for nurturing biotech enterprise: it runs grant and equity schemes, incubators, bio-incubation centres and accelerator programmes that have helped seed much of the 11,800-plus startup base now cited. Its annual Foundation Day, the occasion for this year's release, is the conventional platform for issuing the IBER and the BIRAC Impact Report together.
The policy spine behind the 2030 ambition is the BioE3 Policy — "Biotechnology for Economy, Environment and Employment" — which the Union Cabinet approved on 24 August 2024. BioE3 reframes biotechnology not just as a health or research subject but as an industrial strategy: it seeks to make India a hub for high-performance biomanufacturing, where products presently made through petrochemical or resource-intensive routes are instead grown through biological systems. The financing layer added most recently is the Research, Development & Innovation (RDI) Fund, a Rs 1 lakh crore corpus meant to crowd private capital into deep-tech and sunrise sectors, with BIRAC named among its implementing channels for biotechnology.
BioE3 works through identified thematic sectors rather than as a single grant scheme. Its priority areas span precision biotherapeutics (advanced cell and gene-based medicine), smart proteins and functional foods (alternative and sustainable protein sources), climate-resilient agriculture, bio-based chemicals and enzymes that replace fossil-derived feedstock, fuels through carbon-capture and bioremediation, and the frontiers of marine and space biotechnology. To turn laboratory capability into industrial output it relies on shared infrastructure — bio-foundries, which are automated facilities for designing and testing engineered biological systems at scale, and Bio-AI hubs, which apply artificial intelligence and computing to biological design. The policy also emphasises building a skilled biomanufacturing workforce and regional bio-manufacturing hubs, so that the gains are spread rather than concentrated in a few metros.
For Prelims
- Bioeconomy size: ~USD 10 bn (2014) → USD 195.3 bn (2025); ~17–18% annual growth; ~4.8% of GDP; target USD 300 bn by 2030.
- Startup base: over 11,800 biotech startups underpin the ecosystem.
- BioE3 Policy full form: Biotechnology for Economy, Environment & Employment; approved by the Union Cabinet on 24 August 2024; drives sustainable, high-performance biomanufacturing.
- BioE3 thematic sectors: precision biotherapeutics · smart proteins · climate-resilient agriculture · bio-based / carbon-capture chemicals · marine and space biotech (with bio-foundries and Bio-AI hubs as the delivery infrastructure).
- IBER 2026: the India Bioeconomy Report — the annual measure of the sector — released by BIRAC, alongside the BIRAC Impact Report, at BIRAC's 14th Foundation Day.
- BIRAC: Biotechnology Industry Research Assistance Council — a PSU/Section-8 enterprise of the Department of Biotechnology (DBT), under the Ministry of Science & Technology; the Government's nodal biotech-enterprise agency.
- RDI Fund: Research, Development & Innovation Fund — outlay Rs 1 lakh crore; BIRAC is among its implementers for biotechnology.
- Administering chain: Ministry of Science & Technology → Department of Biotechnology (DBT) → BIRAC (implementation) — under the umbrella of the BioE3 Policy.
What it is NOT: The bioeconomy figure (USD 195.3 bn) is not a budget outlay or a Government spend — it is the estimated economic value generated by bio-based activity across the country. BioE3 is a policy, not a financial scheme with a fixed corpus; the RDI Fund (Rs 1 lakh crore) is the separate financing instrument. BIRAC is a DBT public-sector enterprise — not a statutory regulator and not the DBT itself; it implements and incubates rather than legislates. And the IBER is a report that measures the sector, not a scheme that funds it. Do not confuse the BioE3 Policy with the older National Biotechnology Development Strategy, nor BIRAC with the regulatory bodies that govern gene technology (the Review Committee on Genetic Manipulation and the Genetic Engineering Appraisal Committee).
The set it belongs to (DBT / biotech ecosystem): the Department of Biotechnology (DBT) as the parent; BIRAC as the enterprise-support arm; the BioE3 Policy (2024) as the industrial strategy; the IBER as the annual measurement report; the RDI Fund as the financing layer; and delivery infrastructure such as bio-foundries and Bio-AI hubs. Knowing this chain lets you survive "match the pairs" and "which of these is/are correct" questions linking each name to its exact role.
Why it matters
The significance is partly arithmetic and partly strategic. A bioeconomy that has grown from about USD 10 billion to USD 195.3 billion in a decade, at 17–18% a year, is expanding far faster than the wider economy, and at ~4.8% of GDP it is now a measurable contributor to national output rather than a niche. That growth rests on a wide startup base (11,800-plus firms), which signals depth — value being created across many small innovators, not just a handful of large companies.
Strategically, the BioE3 framing addresses a real problem: many goods India consumes — chemicals, plastics, proteins, fuels — are made through carbon-intensive, import-dependent or resource-heavy routes. Biomanufacturing offers an alternative path in which the same products are grown biologically, lowering the carbon footprint and the import bill while creating skilled jobs. That is the logic behind the policy's three E's — Economy (new output and exports), Environment (lower-emission production) and Employment (a wide biotech workforce). The headline target of USD 300 billion by 2030 makes the sector one of the named pillars of India's sunrise-sector and self-reliance agenda, and the RDI Fund supplies the patient capital that deep-tech ventures typically struggle to raise. For an aspirant, the release is a clean, data-rich example of how science policy is being wired directly into industrial and climate strategy.
It also matters because the bioeconomy connects several syllabus threads at once. On the health side, BIRAC's support has helped bring advanced therapies — including indigenous CAR-T cancer treatments — to market, illustrating how the same ecosystem that drives the headline GDP number also delivers public-health capability. On the agriculture side, climate-resilient crops and bio-inputs tie the bioeconomy directly to farm productivity and food security. And on the climate side, bio-based chemicals and carbon-capture routes link the sector to India's emission-reduction commitments. A single, growing bioeconomy figure therefore sits at the intersection of S&T policy, industrial policy, agriculture and the environment — which is precisely why it recurs in both Prelims fact-recall and Mains analytical questions.
How it compares: India's bioeconomy is among the larger ones globally, but the established frontrunners — notably the United States, the European Union and China — remain ahead in absolute biomanufacturing scale and in commercialising synthetic biology. India's distinct advantage is its breadth of trained scientific manpower, a deep generic-pharmaceutical and vaccine base, and a fast-growing startup layer; the BioE3 Policy is the attempt to convert that base into high-value, made-in-India bio-products rather than ceding the manufacturing step to others. Reading the IBER number against that backdrop is more useful than reading it in isolation.